Representative Laurel M. Lee (R-Florida) recently bought shares of TuHURA Biosciences, Inc. NASDAQ: HURA. In a filing disclosed on August 09th, the Representative disclosed that they had bought between $50,001 and $100,000 in TuHURA Biosciences stock on July 13th.
TuHURA Biosciences Price Performance
Shares of NASDAQ:HURA opened at $3.05 on Tuesday. The stock's 50-day moving average price is $2.57 and its two-hundred day moving average price is $3.23. TuHURA Biosciences, Inc. has a 12-month low of $1.80 and a 12-month high of $8.63.
TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02).
Institutional Investors Weigh In On TuHURA Biosciences
Hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC purchased a new stake in shares of TuHURA Biosciences during the 4th quarter valued at about $1,084,000. Millennium Management LLC purchased a new stake in shares of TuHURA Biosciences during the 4th quarter valued at about $138,000. Squarepoint Ops LLC purchased a new stake in shares of TuHURA Biosciences during the 4th quarter valued at about $223,000. TT Capital Management LLC purchased a new stake in TuHURA Biosciences during the 4th quarter worth approximately $41,000. Finally, Northern Trust Corp purchased a new stake in TuHURA Biosciences during the 4th quarter worth approximately $234,000. 0.62% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on the company. HC Wainwright reaffirmed a "buy" rating and issued a $12.00 price objective on shares of TuHURA Biosciences in a research note on Friday, May 16th. Brookline Capital Management upgraded TuHURA Biosciences to a "strong-buy" rating in a report on Monday, June 23rd. Finally, Wall Street Zen upgraded TuHURA Biosciences from a "sell" rating to a "hold" rating in a report on Friday, July 18th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, TuHURA Biosciences presently has an average rating of "Buy" and an average target price of $12.67.
View Our Latest Stock Analysis on HURA
About Representative Lee
Laurel Lee (Republican Party) is a member of the U.S. House, representing Florida's 15th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.
Lee (Republican Party) is running for re-election to the U.S. House to represent Florida's 15th Congressional District. She declared candidacy for the 2026 election.
Laurel Lee earned undergraduate and law degrees from the University of Florida. Lee's career experience includes working as an attorney with Carlton Fields, P.A., an assistant federal public defender and assistant U.S. attorney with the United States District Court for the Middle District of Florida, and a law clerk to James S. Moody on the United States District Court for the Middle District of Florida. Lee resigned on May 16, 2022.
About TuHURA Biosciences
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access